Загрузка...
Long-term surviving cancer patients as a source of therapeutic TCR
We have established a platform for the isolation of tumour-specific TCR from T cells of patients who experienced clinical benefit from cancer vaccination. In this review we will present the rationale behind this strategy and discuss the advantages of working with “natural” wild type TCRs. Indeed, th...
Сохранить в:
| Опубликовано в: : | Cancer Immunol Immunother |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7183495/ https://ncbi.nlm.nih.gov/pubmed/31915853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-019-02468-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|